Literature DB >> 29119666

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.

A Iorio1,2, V Blanchette3, J Blatny4, P Collins5, K Fischer6, E Neufeld7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29119666     DOI： 10.1111/jth.13867

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  25 in total

1.  Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.

Authors:  João A Abrantes; Siv Jönsson; Mats O Karlsson; Elisabet I Nielsen
Journal:  Br J Clin Pharmacol       Date:  2019-04-29       Impact factor: 4.335

2.  Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization.

Authors:  Alanna McEneny-King; Pierre Chelle; Gary Foster; Arun Keepanasseril; Alfonso Iorio; Andrea N Edginton
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-18       Impact factor: 2.745

3.  Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.

Authors:  Xavier Delavenne; Yesim Dargaud; Edouard Ollier; Claude Négrier
Journal:  Br J Clin Pharmacol       Date:  2019-02-13       Impact factor: 4.335

4.  Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.

Authors:  Pierre Chelle; Cindy H T Yeung; Stacy E Croteau; Jennifer Lissick; Vinod Balasa; Christina Ashburner; Young Shil Park; Santiago Bonanad; Juan Eduardo Megías-Vericat; Azusa Nagao; Tung Wynn; Fernando Corrales-Medina; Huyen Tran; Anjali Sharathkumar; Meera Chitlur; Samuel Sarmiento; Andrea Edginton; Alfonso Iorio
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

Review 5.  How do we optimally utilize factor concentrates in persons with hemophilia?

Authors:  Ming Y Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.

Authors:  Robert Klamroth; Jerzy Windyga; Vlad Radulescu; Peter W Collins; Oleksandra Stasyshyn; Hishamshah Mohd Ibrahim; Werner Engl; Srilatha D Tangada; William Savage; Bruce Ewenstein
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

7.  Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

Authors:  Beth Boulden Warren; Linda Jacobson; Christine Kempton; George R Buchanan; Michael Recht; Deborah Brown; Cindy Leissinger; Amy D Shapiro; Thomas C Abshire; Marilyn J Manco-Johnson
Journal:  Haemophilia       Date:  2019-05-21       Impact factor: 4.263

8.  Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients.

Authors:  Alanna McEneny-King; Pierre Chelle; Margaret H Goggans; Patricia J Barker; Timothy W Jacobs; Ellis J Neufeld; Ulrike M Reiss; John C Panetta
Journal:  Haemophilia       Date:  2021-03-20       Impact factor: 4.263

9.  Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.

Authors:  Manuel Rodríguez López; Juan Eduardo Megías Vericat; Carmen Albo López; Santiago Bonanad
Journal:  BMJ Case Rep       Date:  2020-10-13

10.  Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.

Authors:  Jurg M Sommer; Ali Sadeghi-Khomami; Christopher Barnowski; Margareta Wikén; Annemieke J Willemze
Journal:  Int J Lab Hematol       Date:  2020-03-23       Impact factor: 2.877
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.